Viomycin

Summary

Viomycin (also known as Florimycin or Tuberactinomycin B) is a cyclic peptide antibiotic that was historically employed as an injectable second‑line treatment for drug‑resistant tuberculosis. Administered intramuscularly, it targets the bacterial ribosome and has been withdrawn from the WHO Essential Medicines List, leaving it primarily of research interest today.

Mechanism of Action

Viomycin belongs to the tuberactinomycin family of cyclic peptides that bind to the bacterial ribosome, interfering with protein synthesis. By associating with the ribosomal machinery, it blocks translation elongation, leading to bacteriostatic or bactericidal effects against Mycobacterium tuberculosis. The drug’s antibacterial activity is therefore linked to ribosomal inhibition rather than cell‑wall synthesis.

What the Research Shows

The literature records viomycin as an early tuberactinomycin identified in the 1950s and used as a second‑line anti‑tuberculosis agent (Front Microbiol 2022). A 1984 pharmacokinetic review includes viomycin among twelve antitubercular drugs, indicating its disposition was studied but detailed parameters were not highlighted. A 1970 article examined the combination of ethambutol and viomycin, reflecting clinical use at the time. Recent biosynthetic studies (Front Chem 2024) describe the VioC enzyme that hydroxylates viomycin precursors, shedding light on its natural‑product assembly. Toxicity reviews (Med Toxicol 1987) note ototoxicity as a prominent adverse effect, aligning with known aminoglycoside‑like side‑effects. Overall, research now focuses on its biosynthesis, ribosomal binding mechanisms, and resistance pathways rather than clinical deployment.

Reported Benefits

Historical clinical data demonstrate viomycin’s activity against multidrug‑resistant Mycobacterium tuberculosis, making it a valuable second‑line option before newer agents became available. Its ribosome‑targeting mechanism provides a distinct mode of action compared with first‑line drugs, which contributed to its role in combination regimens for difficult‑to‑treat TB cases.

Limitations of the Evidence

Viomycin has been withdrawn from the WHO Essential Medicines List, and contemporary clinical trials are lacking, limiting current efficacy data. Pharmacokinetic information remains sparse, and resistance mechanisms have emerged, reducing its utility. The need for intramuscular injection and its ototoxic potential further restrict its practical use.

Safety Considerations

The primary safety concern for viomycin is ototoxicity, similar to other aminoglycoside‑type antibiotics, which can lead to irreversible hearing loss. Neuromuscular blockade and other neurological effects have also been reported. Because of these risks, careful monitoring of auditory function is recommended when the drug is used, and it is generally avoided in patients with pre‑existing hearing impairment.

How It Is Administered

Viomycin is formulated for intramuscular injection. It is not available in oral or topical forms, and dosing regimens historically required multiple injections per week. The drug is supplied as a sterile solution for parenteral use.

Routes of Administration

Goals & Uses

• Ribosome function researchResearch ToolHigh
• Multidrug‑resistant tuberculosis treatmentInfectious DiseaseModerate
• HIV reverse transcriptase inhibitionAntiviral ResearchLow
• Treatment of multidrug-resistant tuberculosisAntimicrobialModerate

Contraindications

• Pre‑existing hearing lossAuditoryHigh
• Concurrent use of other nephrotoxic agentsDrug InteractionHigh
• Pre-existing renal impairmentOrgan FunctionHigh
• Pre-existing hearing loss or vestibular dysfunctionAuditory/VestibularHigh
• Severe renal impairmentOrganHighKidney function concerns
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data

Adverse Effects

• NeurotoxicityNeurologicalUncommon
• Injection site reactionsLocalCommon
• OtotoxicityAuditory/vestibularCommon
• Electrolyte disturbancesMetabolicCommon
• Neuromuscular blockadeNeuromuscularRare
• NephrotoxicityRenalCommon

Drug Interactions

• Loop diureticsModerate
• AminoglycosidesHigh
• Neuromuscular blocking agentsModerate
• Aminoglycosides (e.g., streptomycin, kanamycin)High
• Loop diuretics (e.g., furosemide)High

Population Constraints

• Pediatric patientsAgeRelative
• ElderlyAgeRelative
• Elderly patientsAgeRelative
• Pregnant womenReproductiveRelative
• ChildrenPediatricRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization in EU
• United StatesInvestigationalNot FDA‑approved; used in clinical trials for MDR‑TB
• United KingdomUnapprovedNot licensed for clinical use

Viomycin is no longer commercially available as an approved therapeutic in major markets. It was previously used in TB treatment programs but was withdrawn from clinical use. Capreomycin, a closely related tuberactinomycin, replaced it in clinical practice.

Evidence & Sources

• Ethambutol and viomycin
  Journal ArticleModeratePyle MM1970-01-01T00:00:00.000000Z
• Clinical pharmacokinetics of the antituberculosis drugs
  Journal ArticleModerateHoldiness MR1984-01-01T00:00:00.000000Z
• From Genome to Structure and Back Again: A Family Portrait of the Transcarbamylases
  Journal ArticleModerateShi D, Allewell NM, Tuchman M2015-01-01T00:00:00.000000Z
• Catalytic divergencies in the mechanism of L-arginine hydroxylating nonheme iron enzymes
  Journal ArticleModerateAli HS, de Visser SP2024-01-01T00:00:00.000000Z
• Tuberactinomycin antibiotics: Biosynthesis, anti-mycobacterial action, and mechanisms of resistance
  Journal ArticleModerateLaughlin ZT, Conn GL2022-01-01T00:00:00.000000Z
• Neurological manifestations and toxicities of the antituberculosis drugs. A review
  Journal ArticleModerateHoldiness MR1987-01-01T00:00:00.000000Z

Frequently Asked Questions